STAT3 and prostate carcinoma: Previously, we disclosed that targeting STAT3 can inhibit tumour VEGF expression and angiogenesis in prostate cancer cells.45 In addition, we reported recently that STAT3 contributes to castration‐resistant prostate cancer cell survival and chemoresistance.46 Notably, deletion of STAT3 triggered the immunostimulatory induction of the type 1 interferon response, in fibrosarcoma cells, suggesting a key role of STAT3 in the induction of ICD.31, 32 However, whether STAT3 plays an important part in oncolytic NDV‐elicited ICD in prostate cancer cells has not been investigated.